What is the recommended initial management of hypertension in adults, including lifestyle modifications and first‑line pharmacologic therapy?

Initial Management of Hypertension in Adults

For most adults with confirmed hypertension (BP ≥140/90 mmHg), initiate combination pharmacologic therapy with two first-line agents—specifically a RAS blocker (ACE inhibitor or ARB) combined with either a dihydropyridine calcium channel blocker or thiazide/thiazide-like diuretic—preferably as a single-pill combination, alongside comprehensive lifestyle modifications. 1

Lifestyle Modifications (First-Line for All Patients)

All patients with elevated BP or hypertension require lifestyle interventions, which provide additive BP-lowering effects and enhance medication efficacy: 2

• Weight loss if overweight or obese 2
• Dietary sodium restriction (low sodium intake) combined with potassium supplementation (high potassium intake) 2
• Healthy dietary pattern (such as DASH diet) 2, 3
• Regular physical activity 2
• Alcohol moderation or elimination 2

For adults with elevated BP (120-139/70-89 mmHg) and low-to-medium cardiovascular risk (<10% over 10 years), lifestyle measures alone are recommended initially. 1 However, if BP remains ≥130/80 mmHg after 3 months of lifestyle intervention in those with sufficiently high CVD risk, pharmacologic treatment should be initiated. 1

Pharmacologic Therapy

When to Initiate Medication

• Confirmed BP ≥140/90 mmHg: Initiate pharmacologic treatment promptly regardless of CVD risk, combined with lifestyle measures 1
• BP ≥130/80 mmHg with high CVD risk: After 3 months of lifestyle intervention, initiate medication if BP remains elevated 1
• Stage 2 hypertension (BP >20/10 mmHg above target): Start with two-drug combination therapy 4

First-Line Medication Classes

The three preferred first-line drug classes have demonstrated the most effective reduction in BP and cardiovascular events: 1

• Thiazide or thiazide-like diuretics (hydrochlorothiazide, chlorthalidone, indapamide) 1, 2
• ACE inhibitors or ARBs (RAS blockers such as enalapril or candesartan) 1, 2
• Dihydropyridine calcium channel blockers (such as amlodipine) 1, 2

Recommended Initial Combination Therapy

For most patients with confirmed hypertension (BP ≥140/90 mmHg), combination therapy is recommended as initial treatment rather than monotherapy, as trial evidence demonstrates more effective BP control: 1

• Preferred combinations: RAS blocker (ACE inhibitor or ARB) + dihydropyridine CCB, OR RAS blocker + thiazide/thiazide-like diuretic 1
• Fixed-dose single-pill combinations are strongly recommended to improve adherence 1

Exceptions to initial combination therapy include: 1

• Patients aged ≥85 years
• Symptomatic orthostatic hypotension
• Moderate-to-severe frailty
• Elevated BP (120-139/70-89 mmHg) with concomitant indication for treatment

Escalation Strategy

If BP remains uncontrolled on two-drug combination: 1

• Increase to three-drug combination: RAS blocker + dihydropyridine CCB + thiazide/thiazide-like diuretic
• Preferably use single-pill combination formulation 1

Important caveat: Never combine two RAS blockers (ACE inhibitor + ARB together) 1

Special Considerations for Beta-Blockers

Beta-blockers are not first-line agents for uncomplicated hypertension. They should be combined with other major BP-lowering drug classes only when compelling indications exist: 1

• Angina
• Post-myocardial infarction
• Heart failure with reduced ejection fraction (HFrEF)
• Heart rate control

Blood Pressure Targets

Target systolic BP of 120-129 mmHg is recommended for most adults to reduce cardiovascular risk, provided treatment is well tolerated. 1 The 2024 ESC guidelines represent the most recent high-quality evidence prioritizing this intensive target.

• ACC/AHA 2017 guidelines recommend <130/80 mmHg for adults with known CVD or 10-year ASCVD risk ≥10% 4
• If the 120-129 mmHg target is poorly tolerated, apply the ALARA principle ("as low as reasonably achievable") 1

Medication Timing and Adherence

• Take medications at the most convenient time of day to establish habitual patterns and improve adherence 1
• Monthly follow-up is recommended after initiating or adjusting drug regimens until BP control is achieved 4
• Lifelong treatment is recommended, even beyond age 85 years, if well tolerated 1

Common Pitfalls to Avoid

• Monotherapy in stage 2 hypertension: Most patients require combination therapy; starting with single agents delays control 1
• Using separate pills instead of fixed-dose combinations: This reduces adherence 1
• Combining ACE inhibitor + ARB: This combination is contraindicated 1
• Inadequate follow-up: Monthly monitoring is essential until control is achieved 4
• Discontinuing treatment in elderly patients: Continue lifelong if tolerated 1